Biocon, Asia’s premier biopharmaceuticals company, has inaugurated a world class facility for manufacturing new generation, patient-friendly devices for its insulins portfolio. The 100,000 square feet, state-of-the-art new devices facility set up in Bangalore will enable the company to leverage the country’s manufacturing expertise to develop world-class delivery devices for people with diabetes in India and other parts of the world.
The pharma major has also launched Basalog One, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility. Basalog One, a long acting basal insulin glargine presented as an innovative, pre-filled pen, is the first product to roll out of this facility.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
